Save over 50% on brand Halaven imported from Europe and 78% on generic Halaven.
Click here for information on Cipla generics (Immediate availability)
All European Halaven is manufactured by:
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
Information about Halaven
Halaven is a chemotherapy medication that contains eribulin mesylate. It is primarily used to treat certain types of breast cancer and is derived from a natural compound found in the marine sponge Haliclona (formerly Ectyoplasia) turbinata. Eribulin acts by inhibiting microtubule dynamics, effectively disrupting cell division.
Product Highlights
- Indicated for patients with metastatic breast cancer who have previously received at least two chemotherapy regimens for metastatic disease.
- May be used for patients with locally advanced disease that cannot be treated with surgery.
- A unique class of microtubule inhibitor that impedes cancer cell division.
Key Ingredient
Key Benefits
- Studies have shown that eribulin can improve overall survival in some patients with metastatic breast cancer.
- May be better tolerated than some traditional chemotherapy agents, with a different side effect profile.
- Administered in cycles, typically every 21 days, which allows for more manageable treatment schedules.
Direction of Use
- Given intravenously by a healthcare professional, usually over 2 to 5 minutes.
- The typical dosage is 1.4 mg/m² of body surface area, administered on days 1 and 8 of a 21-day cycle.
- Regular blood tests are required to monitor blood cell counts and liver function during treatment.
Safety Concerns
- May include fatigue, nausea, hair loss, peripheral neuropathy, and low blood cell counts (neutropenia).
- Due to potential decreases in white blood cell counts, patients are at increased risk for infections.
- Patients with a history of heart disease should be monitored, as there is a potential risk of cardiac toxicity.
Avoid Halaven If
- Known allergy to eribulin or any of its components.
- Patients with significantly low white blood cell counts should not use halaven.
- Not advised during pregnancy or breastfeeding due to possible risks to the fetus or infant.
- Caution is advised in patients with severe liver dysfunction, as dosage adjustments may be necessary.
